RS BioTherapeutics Announces Research Collaboration with University of Colorado School of Medicine
08 juil. 2024 10h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., July 08, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from deadly lung diseases...
RS BioTherapeutics Launches Crowdfunding Campaign Through StartEngine
30 avr. 2024 10h00 HE
|
RS BioTherapeutics
RS BioTherapeutics announced today the launch of an SEC Regulation Crowdfunding (Reg CF) investment campaign through StartEngine.
RS BioTherapeutics Adds Jane Wright-Mitchell, Pharm.D., J.D. to Business Advisory Board
25 avr. 2024 10h00 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce the addition of Jane Wright-Mitchell, Pharm.D., J.D. to the RS BioTherapeutics Business Advisory Board.
RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
18 mars 2024 11h30 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce that its submission has been selected for a poster presentation at the 2024 Respiratory Innovation Summit
RS BioTherapeutics Creates Therapeutic Expert Council to Provide Guidance on Development of First-in-Class Agent Focused on Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis
21 févr. 2024 09h52 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce the formation of its Therapeutic Expert Council (TEC).
RS BioTherapeutics Promotes Michelle L. Shuffett, MD to Chief Medical Officer
31 oct. 2023 11h00 HE
|
RS BioTherapeutics
RS BioTherapeutics is pleased to announce that it has appointed Michelle L. Shuffett, MD as its Chief Medical Officer.
RS BioTherapeutics and National Institutes of Health Execute Research Collaboration Agreement to Evaluate Prevention and Treatment of Idiopathic Pulmonary Fibrosis
29 août 2023 11h30 HE
|
RS BioTherapeutics
CUMBERLAND, Md., Aug. 29, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, a life sciences company developing life-changing medicines for the millions of people suffering from diseases characterized by...
RS BioTherapeutics Appoints Michelle L. Shuffett, MD as SVP of Medical and Scientific Affairs
05 juin 2023 07h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., June 05, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Joins BioNTX Bioscience and Healthcare Innovation Trade Organization
15 mai 2023 10h00 HE
|
RS BioTherapeutics
CUMBERLAND, Md., May 15, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of cannabinoids in the research, development, and commercialization of life...
RS BioTherapeutics Announces Filing of Provisional Plant Patent Application for New Cultivar to Serve as Botanical Raw Material Source for First Compound
01 mai 2023 10h13 HE
|
RS BioTherapeutics
CUMBERLAND, Md., May 01, 2023 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to harness the therapeutic power of Cannabinoids in the research, development, and commercialization of life...